Education
About Us
Working with TipRanks
Follow Us
Zhongzhi Pharmaceutical Holdings Limited (HK:3737)
:3737
3737 Stock Chart & Stats
HK$0.88
HK$0.04(4.04%)
At close: 4:00 PM EST
HK$0.88
HK$0.04(4.04%)
Day’s Range― - ―
52-Week RangeHK$0.50 - HK$1.00
Previous CloseN/A
Volume157.00K
Average Volume (3M)412.77K
Market Cap
HK$618.31M
Enterprise ValueHK$545.87M
Total Cash (Recent Filing)HK$176.31M
Total Debt (Recent Filing)HK$139.50M
Price to Earnings (P/E)27.8
Beta0.03
Next Earnings
Mar 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield9.43%
Share Statistics
EPS (TTM)0.01
Shares Outstanding863,600,000
10 Day Avg. Volume391,300
30 Day Avg. Volume412,766
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)0.70
Price to Sales (P/S)0.35
P/FCF Ratio19.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Robust Balance SheetA consistently high equity ratio and low debt-to-equity (~0.20) provide durable financial flexibility. This capital structure supports continued R&D, manufacturing investment, and dividend payments while allowing the company to absorb industry shocks and pursue opportunistic M&A without immediate financing strain.
High Gross MarginsSustained gross margins above 57% indicate efficient cost of goods sold and potential pricing power in specialty & generic drugs. High base gross profitability gives room to withstand rising SG&A or input costs and supports long-term operating leverage as revenues scale.
Multi-year Revenue GrowthMeaningful revenue expansion over several years signals durable market demand and successful commercial execution. Growing top-line provides scale to spread fixed costs, fund product development, and deepen customer relationships, strengthening competitive position over the medium term.
Bears Say
Declining Profitability MarginsMaterial erosion in net and operating margins points to structural cost pressures, pricing erosion, or rising SG&A. Persistently lower margins compress retained earnings and ROE, reducing reinvestment capacity and the firm's ability to sustain dividends or fund growth without improving operational efficiency.
Volatile And Negative Free Cash FlowInconsistent and recently negative free cash flow undermines the company's ability to self-fund capex, R&D, and dividends. Over the medium term this raises reliance on external financing despite low leverage, increasing execution risk if cash generation does not stabilize.
Declining Cash And ROEA shrinking cash buffer combined with falling ROE signals weakening profitability efficiency and liquidity headroom. This persistent deterioration can constrain strategic flexibility, slow investment cadence, and elevate vulnerability to adverse industry or regulatory shocks over the next several quarters.
Zhongzhi Pharmaceutical Holdings Limited News
3737 FAQ
What was Zhongzhi Pharmaceutical Holdings Limited’s price range in the past 12 months?
Zhongzhi Pharmaceutical Holdings Limited lowest stock price was HK$0.50 and its highest was HK$1.00 in the past 12 months.
What is Zhongzhi Pharmaceutical Holdings Limited’s market cap?
Zhongzhi Pharmaceutical Holdings Limited’s market cap is HK$618.31M.
When is Zhongzhi Pharmaceutical Holdings Limited’s upcoming earnings report date?
Zhongzhi Pharmaceutical Holdings Limited’s upcoming earnings report date is Mar 19, 2026 which is in 25 days.
How were Zhongzhi Pharmaceutical Holdings Limited’s earnings last quarter?
Zhongzhi Pharmaceutical Holdings Limited released its earnings results on Aug 26, 2025. The company reported HK$0.011 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.011.
Is Zhongzhi Pharmaceutical Holdings Limited overvalued?
According to Wall Street analysts Zhongzhi Pharmaceutical Holdings Limited’s price is currently Overvalued.
Does Zhongzhi Pharmaceutical Holdings Limited pay dividends?
Zhongzhi Pharmaceutical Holdings Limited pays a Annually dividend of HK$0.05 which represents an annual dividend yield of 9.43%. See more information on Zhongzhi Pharmaceutical Holdings Limited dividends here
What is Zhongzhi Pharmaceutical Holdings Limited’s EPS estimate?
Zhongzhi Pharmaceutical Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zhongzhi Pharmaceutical Holdings Limited have?
Zhongzhi Pharmaceutical Holdings Limited has 863,600,000 shares outstanding.
What happened to Zhongzhi Pharmaceutical Holdings Limited’s price movement after its last earnings report?
Zhongzhi Pharmaceutical Holdings Limited reported an EPS of HK$0.011 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.22%.
Which hedge fund is a major shareholder of Zhongzhi Pharmaceutical Holdings Limited?
Currently, no hedge funds are holding shares in HK:3737
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zhongzhi Pharmaceutical Holdings Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.77%
12-Months-Change
Fundamentals
Return on Equity
1.87%
Trailing 12-Months
Asset Growth
-4.21%
Trailing 12-Months
Company Description
Zhongzhi Pharmaceutical Holdings Limited
Zhongzhi Pharmaceutical Holdings Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company operates through three segments: Pharmaceutical Manufacturing, Operation of Chain Pharmacies, and Operation of On-Line Pharmacies. It provides Chinese patent medicines and decoction pieces under the Zeus, Liumian, and Caojinghua brands. The company is also manufacture and sale of food and Chinese herbs; property management; and pharmaceutical drugs, as well as offers detection and testing services. As of December 31, 2021, it operated 398 self-operated chain pharmacies, including 361 medical insurance designated pharmacies located in Zhongshan in the Guangdong Province under the Zeus brand. The company was founded in 1993 and is headquartered in Zhongshan, the People's Republic of China. Zhongzhi Pharmaceutical Holdings Limited is a subsidiary of Crystal Talent Investment Group Limited.
Technical Analysis
Wai Yuen Tong Medicine Holdings Limited
―
Lee's Pharmaceutical Holdings Limited
―
PuraPharm Corp. Ltd.
―
Fusen Pharmaceutical Co., Ltd.
―
Pak Fah Yeow International Limited
―
Options Prices
Currently, No data available
---